1-2 of 2
Cecilia Carpio
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia

Eytan M. Stein, Daniel J. DeAngelo, Jörg Chromik, Manik Chatterjee, Sebastian Bauer, Chia-Chi Lin, Cristina Suarez, Filip de Vos, Neeltje Steeghs, Philippe A. Cassier, David Tai, Jean-Jacques Kiladjian, Noboru Yamamoto, Rogier Mous, Jordi Esteve, Hironobu Minami, Stephane Ferretti, Nelson Guerreiro, Christophe Meille, Rajkumar Radhakrishnan, Bernard Pereira, Luisa Mariconti, Ensar Halilovic, Claire Fabre, Cecilia Carpio
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 870–881.
https://doi.org/10.1158/1078-0432.CCR-21-1295
Published: 01 March 2022
View article titled, Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type <em>TP53</em> Solid Tumors and Acute Leukemia
Open the PDF for Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type <em>TP53</em> Solid Tumors and Acute Leukemia in another window
Includes: Supplementary data
Journal Articles

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma

Leo I. Gordon, Jason B. Kaplan, Rakesh Popat, Howard A. Burris, III, Silvia Ferrari, Sumit Madan, Manish R. Patel, Giuseppe Gritti, Dima El-Sharkawi, Ian Chau, John A. Radford, Jaime Pérez de Oteyza, Pier Luigi Zinzani, Swaminathan Iyer, William Townsend, Reem Karmali, Harry Miao, Igor Proscurshim, Shining Wang, Yujun Wu, Kate Stumpo, Yaping Shou, Cecilia Carpio, Francesc Bosch
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (14): 3546–3556.
https://doi.org/10.1158/1078-0432.CCR-19-3239
Published: 15 July 2020
View article titled, Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma
Open the PDF for Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma in another window
Includes: Supplementary data